Crystal structures of cholesteryl ester transfer protein in complex with inhibitors

Journal of Biological Chemistry

Volumn 287, Issue 44, 2012, Pages 37321-37329

  Liu, Shenping ^a   Mistry, Anil ^a,b   Reynolds, Jennifer M ^a   Lloyd, David B ^a,c   Griffor, Matthew C ^a   Perry, David A ^a   Ruggeri, Roger B ^a   Clark, Ronald W ^a   Qiu, Xiayang ^a  

^a PFIZER INC   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NABSYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL STUDIES; CHOLESTERYL ESTER TRANSFER PROTEINS; CHOLESTERYL ESTERS; INHIBITION MECHANISMS; LOW DENSITY LIPOPROTEINS; POLAR INTERACTIONS; SMALL MOLECULES;

ESTERS; PROTEINS;

ESTERIFICATION;

3 [[4 (4 CHLORO 3 ETHYLPHENOXY)PYRIMIDIN 2YL][3 (1,1,2,2 TETRAFLUOROEXTHOXY)BENZYL]AMINO] 1,1,1 TRIFLUOROPROPAN 2 OL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HISTIDINE; PHOSPHOLIPID; SERINE; TORCETRAPIB; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; HYDROPHOBICITY; ILLUMINATION; LIPID TRANSPORT; LIPOPHILICITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE;

AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; BINDING SITES; CHOLESTEROL ESTER TRANSFER PROTEINS; CRYSTALLOGRAPHY, X-RAY; FLUOROCARBONS; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; QUINOLINES;

EID: 84868256894     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.380063     Document Type: Article

References (47)

1. Bruckert, E., and Hansel, B. (2007) HDL-c is a powerful lipid predictor of cardiovascular diseases. Int. J. Clin. Pract. 61, 1905-1913
2. Barter, P. J., Brewer, H. B., Jr., Chapman, M. J., Hennekens, C. H., Rader, D. J., and Tall, A. R. (2003) Cholesteryl ester transfer protein: a novel target for raisingHDLand inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 160-167
3. Qiu, X., Mistry, A., Ammirati, M. J., Chrunyk, B. A., Clark, R. W., Cong, Y., Culp, J. S., Danley, D. E., Freeman, T. B., Geoghegan, K. F., Griffor, M. C., Hawrylik, S. J., Hayward, C. M., Hensley, P., Hoth, L. R., Karam, G. A., Lira, M. E., Lloyd, D. B., McGrath, K. M., Stutzman-Engwall, K. J., Subashi, A. K., Subashi, T. A., Thompson, J. F., Wang, I. K., Zhao, H., and Seddon, A. P. (2007) Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat. Struct. Mol. Biol. 14, 106-113
4. Brown, M. L., Inazu, A., Hesler, C. B., Agellon, L. B., Mann, C., Whitlock, M. E., Marcel, Y. L., Milne, R. W., Koizumi, J., and Mabuchi, H. (1989) Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342, 448-451
5. Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., and Tall, A. R. (1990) Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323, 1234-1238
6. Agellon, L. B., Walsh, A., Hayek, T., Moulin, P., Jiang, X. C., Shelanski, S. A., Breslow, J. L., and Tall, A. R. (1991) Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol. Chem. 266, 10796-10801
7. Sugano, M., Makino, N., Sawada, S., Otsuka, S., Watanabe, M., Okamoto, H., Kamada, M., and Mizushima, A. (1998) Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273, 5033-5036
8. Linsel-Nitschke, P., and Tall, A. R. (2005) HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug. Discov. 4, 193-205
9. Dullaart, R. P., Dallinga-Thie, G. M., Wolffenbuttel, B. H., and van Tol, A. (2007) CETP inhibition in cardiovascular risk management: a critical appraisal. Eur. J. Clin. Invest. 37, 90-98
10. Joy, T., and Hegele, R. A. (2008) Is raising HDL a futile strategy for atheroprotection? Nat. Rev. Drug. Discov. 7, 143-155
11. Cannon, C. P. (2011) High-density lipoprotein cholesterol as the Holy Grail. Jama 306, 2153-2155
12. World Health Organization (2008) The Atlas of Heart Disease and Stroke, World Health Organization, Geneva, Switzerland
13. Ruggeri, R. B. (2005) Cholesteryl ester transfer protein: pharmacological inhibition for the modulation of plasma cholesterol levels and promising target for the prevention of atherosclerosis. Curr. Top Med. Chem. 5, 257-264
14. Krishna, R., Anderson, M. S., Bergman, A. J., Jin, B., Fallon, M., Cote, J., Rosko, K., Chavez-Eng, C., Lutz, R., Bloomfield, D. M., Gutierrez, M., Doherty, J., Bieberdorf, F., Chodakewitz, J., Gottesdiener, K. M., and Wagner, J. A. (2007) Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 370, 1907-1914
15. Ali, A., Napolitano, J. M., Deng, Q., Lu, Z., Sinclair, P. J., Taylor, G. E., Thompson, C. F., Quraishi, N. (July 1, 2005) U. S. Patent 2006/0040999 A1
16. Cao, G., Beyer, T. P., Zhang, Y., Schmidt, R. J., Chen, Y. Q., Cockerham, S. L., Zimmerman, K. M., Karathanasis, S. K., Cannady, E. A., Fields, T., and Mantlo, N. B. (2011) Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J. Lipid Res. 52, 2169-2176
17. Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K., and Shinkai, H. (2000) A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406, 203-207
18. Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J. C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., and Brewer, B. (2007) Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122
19. Nissen, S. E., Tardif, J. C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., Lasala, G. P., Tuzcu, E. M., and ILLUSTRATE Investigators (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304-1316
20. Kastelein, J. J., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., Duggan, W. T., and Bots, M. L. (2007) Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356, 1620-1630
21. Bots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., and Kastelein, J. J. (2007) Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomized, doubleblind trial. Lancet 370, 153-160
22. Hooper, A. J., and Burnett, J. R. (2012) Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opin. Investig. Drugs 21, 1427-1432
23. Vergeer, M., and Kastelein, J. J. (2008) Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia. Nat. Clin. Pract. Cardiovasc Med. 5, 302-303
24. Stein, E. A., Roth, E. M., Rhyne, J. M., Burgess, T., Kallend, D., and Robinson, J. G. (2010) Safety and tolerability of dalcetrapib (RO4607381/JTT- 705): results from a 48-week trial. Eur. Heart. J. 31, 480-488
25. Nicholls, S. J., Brewer, H. B., Kastelein, J. J., Krueger, K. A., Wang, M. D., Shao, M., Hu, B., McErlean, E., and Nissen, S. E. (2011) Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. Jama 306, 2099-2109
26. Tall, A. R., Yvan-Charvet, L., and Wang, N. (2007) The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. 27, 257-260
27. Tall, A. R. (2007) CETP inhibitors to increase HDL cholesterol levels. N. Engl. J. Med. 356, 1364-1366
28. Joy, T., and Hegele, R. A. (2009) The end of the road for CETP inhibitors after torcetrapib? Curr. Opin. Cardiol. 24, 364-371
29. Hamilton, J. A., and Deckelbaum, R. J. (2007) Crystal structure of CETP: new hopes for raising HDL to decrease risk of cardiovascular disease? Nat. Struct. Mol. Biol. 14, 95-97
30. Clark, R. W., Ruggeri, R. B., Cunningham, D., and Bamberger, M. J. (2006) Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J. Lipid Res. 47, 537-552
31. Zhang, L., Yan, F., Zhang, S., Lei, D., Charles, M. A., Cavigiolio, G., Oda, M., Krauss, R. M., Weisgraber, K. H., Rye, K. A., Pownall, H. J., Qiu, X., and Ren, G. (2012) Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat. Chem. Biol. 8, 342-349
32. Otwinowski, Z., Borek, D., Majewski, W., and Minor, W. (2003) Multiparametric scaling of diffraction intensities. Acta Crystallogr. A 59, 228-234
33. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760-763
34. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501
35. Lloyd, D. B., Reynolds, J. M., Cronan, M. T., Williams, S. P., Lira, M. E., Wood, L. S., Knight, D. R., and Thompson, J. F. (2005) Novel variants in human and monkey CETP. Biochim. Biophys. Acta 1737, 69-75
36. Lloyd, D. B., Lira, M. E., Wood, L. S., Durham, L. K., Freeman, T. B., Preston, G. M., Qiu, X., Sugarman, E., Bonnette, P., Lanzetti, A., Milos, P. M., and Thompson, J. F. (2005) Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib. J. Biol. Chem. 280, 14918-14922
37. Damon, D. B., Dugger, R. W., and Scott, R. W. (April 18, 2003) U. S. Patent 6706881
38. Chang, G., Garigipati, R. S., Lefker, B., Perry, D. A., and Zeng, D. (Jan 3, 2007) U. S. Patent 7919506
39. Gumkowski, M. J., Franco, L., Murdande, S. B., and Perlman, M. E. (June 19, 2002) U. S. Patent 6962931
40. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 46, 3-26
41. Ranalletta, M., Bierilo, K. K., Chen, Y., Milot, D., Chen, Q., Tung, E., Houde, C., Elowe, N. H., Garcia-Calvo, M., Porter, G., Eveland, S., Frantz- Wattley, B., Kavana, M., Addona, G., Sinclair, P., Sparrow, C., O'Neill, E. A., Koblan, K. S., Sitlani, A., Hubbard, B., and Fisher, T. S. (2010) Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res. 51, 2739-2752
42. Howes, L. G., and Kostner, K. (2007) The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism. Expert Opin. Investig. Drugs 16, 1509-1516
43. Forrest, M. J., Bloomfield, D., Briscoe, R. J., Brown, P. N., Cumiskey, A. M., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., Messina, E., Peterson, L. B., Sharif-Rodriguez, W., Siegl, P. K., Sinclair, P. J., Sparrow, C. P., Stevenson, A. S., Sun, S. Y., Tsai, C., Vargas, H., Walker, M., 3rd, West, S. H., White, V., and Woltmann, R. F. (2008) Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J. Pharmacol. 154, 1465-1473
44. Barter, P. J., Nicholls, S., Rye, K. A., Anantharamaiah, G. M., Navab, M., and Fogelman, A. M. (2004) Antiinflammatory properties of HDL. Circ. Res. 95, 764-772
45. Yvan-Charvet, L., Matsuura, F., Wang, N., Bamberger, M. J., Nguyen, T., Rinninger, F., Jiang, X. C., Shear, C. L., and Tall, A. R. (2007) Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler. Thromb. Vasc. Biol. 27, 1132-1138
46. Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., Chea, H., Knopp, R. H., Brunzell, J., Geary, R., Chait, A., Zhao, X. Q., Elkon, K., Marcovina, S., Ridker, P., Oram, J. F., and Heinecke, J. W. (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117, 746-756
47. Pecheniuk, N. M., Deguchi, H., Elias, D. J., Xu, X., and Griffin, J. H. (2006) Cholesteryl ester transfer protein genotypes associated with venous thrombosis and dyslipoproteinemia in males. J. Thromb. Haemost. 4, 2080-2082